Los Angeles Capital Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Los Angeles Capital Management LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 17.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 121,000 shares of the biopharmaceutical company’s stock after purchasing an additional 17,716 shares during the period. Los Angeles Capital Management LLC owned 0.10% of Halozyme Therapeutics worth $4,922,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. TD Asset Management Inc boosted its position in shares of Halozyme Therapeutics by 517.0% in the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after buying an additional 1,662,390 shares during the period. Norges Bank purchased a new position in Halozyme Therapeutics in the 4th quarter worth approximately $44,935,000. Epoch Investment Partners Inc. grew its position in Halozyme Therapeutics by 250.5% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after acquiring an additional 831,199 shares in the last quarter. Boston Partners raised its stake in shares of Halozyme Therapeutics by 562.2% during the fourth quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock valued at $20,218,000 after purchasing an additional 468,977 shares during the period. Finally, LSV Asset Management acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $17,090,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $45.38, for a total value of $453,800.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at $7,631,826.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 30,000 shares of company stock worth $1,338,800 over the last quarter. 2.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Benchmark restated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $48.00 to $51.00 in a research report on Friday, June 7th. Finally, JMP Securities decreased their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $54.13.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $50.86 on Friday. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The company has a market capitalization of $6.47 billion, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 0.51 and a beta of 1.28. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $53.00. The business has a 50 day simple moving average of $43.67 and a 200-day simple moving average of $39.97.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.07. The firm had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.